T. Rowe Price Associates
UNCY icon

T. Rowe Price Associates’s Unicycive Therapeutics UNCY Stock Holding History

T. Rowe Price Associates’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95K Buy
+20,048
New +$148K ﹤0.01% 3151

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

T. Rowe Price Associates's UNCY Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 20,048 shares worth $95K. The stake represents ﹤0.01% of the portfolio and ranks #3151 among its holdings.

80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • T. Rowe Price Associates held 20,048 shares of Unicycive Therapeutics worth $95K as of Q2 2026.
  • Unicycive Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3151 holding.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.